What Eli Lilly, Novo Nordisk earnings reveal about the future of GLP-1 sales

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 29 sec. here
  • 8 min. at publisher
  • 📊 Quality Score:
  • News: 36%
  • Publisher: 63%

Novo Nordisk ニュース

Eli Lilly,Weight Loss,Weight-Loss Drug

GLP-1s continue to fuel investor interest in market competition, as companies prepare to differentiate themselves in the coming year.

missed second quarter Wall Street estimatesfor its GLP-1 sales. It beat Wall Street quarterly sales projections by 13% — with total sales of $4.3 billion for weight-loss drug Zepbound and diabetes drug Mounjaro. The stock surged more than 10% on Thursday as a result of Lilly signaling the easing of supply constraints helped Novo too. Its stock rose 5% that day.

Which is why some say market moves based on quarterly results in the near term isn't a good strategy. PARIS — Three German swimmers became ill after competing in the open water races at the Paris Olympics, though it was not immediately clear if the long-polluted Seine River was responsible for their sickness.

Jimmy Fallon has worked with Steph Curry before, so maybe it was easy for the superstar who delivered an all-timer of a performance for Olympic gold to pose for the Tonight Show host in the middle of a game. Because that's exactly what happened.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 47. in JP

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Excitement grows around Eli Lilly's GLP-1 drugs in Q2 earningsShares of Eli Lilly (LLY) are jumping after the company posted second quarter earnings results, beating expectations on both the top and bottom lines. The...
ソース: YahooFinanceCA - 🏆 47. / 63 続きを読む »

What Eli Lilly, Novo Nordisk earnings show about GLP-1 salesRecent earnings from Eli Lilly and Company (LLY) and Novo Nordisk (NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created...
ソース: YahooFinanceCA - 🏆 47. / 63 続きを読む »